<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016261</url>
  </required_header>
  <id_info>
    <org_study_id>A13-996</org_study_id>
    <nct_id>NCT02016261</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Cognitive Functioning in Remitted Depression During Treatment With Fluvoxamine</brief_title>
  <official_title>Open Label, Non-comparative Study to Evaluate Cognitive Functioning in Remitted Depression Outpatients During Long-term Preventive Treatment With Fluvoxamine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moscow Research Institute of Psychiatry</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Moscow Research Institute of Psychiatry</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, non-comparative, prospective study to evaluate cognitive functioning in remitted
      depression outpatients during long-term preventive treatment with Fluvoxamine (Fevarin®)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of time difference between Part I and Part II of Stroop Test</measure>
    <time_frame>From baseline up to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of total Frontal Assessment Battery score</measure>
    <time_frame>From baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients maintained remission status</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Addenbrooke's Cognitive Examination general score</measure>
    <time_frame>From baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of The Social Adaptation Self-evaluation Scale total score</measure>
    <time_frame>From baseline up to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Recurrent Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Remitted Depression Outpatients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults 18-65 years old, males and females with the diagnosis of recurrent depressive disorder and who had at least two severe depressive episodes (with or without psychotic symptoms) of the disorder and who currently in remission</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvoxamine</intervention_name>
    <description>The subjects will be prescribed Fluvoxamine treatment for 24 weeks with dose 50-300 mg</description>
    <arm_group_label>Remitted Depression Outpatients</arm_group_label>
    <other_name>Fevarin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of recurrent depressive disorder at least two years prior to enrollment into
             the study.

          2. At least two severe depressive episodes with or without psychotic symptoms in the past
             medical history.

          3. Stable patient in remission since at least 4 weeks after depressive episode and not
             more than 6 months after depressive episode.

          4. Planned prescription of fluvoxamine for preventive therapy in recurrent depressive
             disorder.

          5. The subject is fluent in Russian language.

          6. According to Stroop test one of following points has to be met - increase of the words
             reading time on 10% and more or three and more mistakes done.

          7. Sum of Addenbrooke's Cognitive Examination total scores must be 93 or less.

          8. Male or female, between the ages of 18 and 65 years.

          9. If female, postmenopausal or birth control.

        Exclusion Criteria:

          1. Diagnosis of the following concomitant psychiatric disorders: current depressive or
             maniac episode, bipolar affective disorder, persistent mood affective disorder
             (cyclothymia, dysthymia, other or unspecified persistent mood disorder), other or
             unspecified mood affective disorder, substance-related disorders, schizophrenia, or
             other psychotic disorders.

          2. History of a drug or alcohol disorder.

          3. Current treatment with fluvoxamine.

          4. History of depressive disorder associated with endocrine disorders.

          5. Pregnancy, breast-feeding female patients.

          6. History of any significant neurologic disease.

          7. Treatment with electroconvulsive therapy in the 6 months preceding the study.

          8. Major risk of suicide.

          9. Hypersensitivity to fluvoxamine.

         10. Use of the medications, which are known to interact with fluvoxamine.

         11. Have initiated psychotherapy or other therapies (such as acupuncture or hypnosis).

         12. Have initiated cognitive remediation therapy within 12 weeks prior enrollment or at
             any time during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexey E. Bobrov, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moscow Research Institution of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moscow Research Institution of Psychiatry</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2013</study_first_submitted>
  <study_first_submitted_qc>December 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2013</study_first_posted>
  <last_update_submitted>July 20, 2015</last_update_submitted>
  <last_update_submitted_qc>July 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cognitive function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluvoxamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

